Pharma & Healthcare

Global Cancer Biopharmaceuticals Market Insights, Forecast to 2030

Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Cancer is a complex invasive genetic disease that causes significant mortality rate worldwide. Cancer drugs are the primary concern in terms of drug development trends.
Market Analysis and Insights: Global Cancer Biopharmaceuticals Market
The global Cancer Biopharmaceuticals market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Cancer Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Cancer Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Cancer Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Cancer Biopharmaceuticals include Sanofi, Johnson & Johnson, Pfizer, Novartis, Merck, GlaxoSmithKline, Eli Lilly, Agios Pharmaceuticals and Bristol-Myers Squibb, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Cancer Biopharmaceuticals is widely used in various fields, such as Liquid Cancers and Solid Cancers, etc. Liquid Cancers provides greatest supports to the Cancer Biopharmaceuticals industry development. In 2023, global % revenue of Cancer Biopharmaceuticals went into Liquid Cancers filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Cancer Biopharmaceuticals market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Cancer Biopharmaceuticals, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Cancer Biopharmaceuticals, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Cancer Biopharmaceuticals revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Cancer Biopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Cancer Biopharmaceuticals revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Sanofi
Johnson & Johnson
Pfizer
Novartis
Merck
GlaxoSmithKline
Eli Lilly
Agios Pharmaceuticals
Bristol-Myers Squibb
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Segment by Type
Biologics
Biosimilars
Segment by Application
Liquid Cancers
Solid Cancers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Cancer Biopharmaceuticals in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Biopharmaceuticals companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Biopharmaceuticals revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Biopharmaceuticals Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Biologics
1.2.3 Biosimilars
1.3 Market by Application
1.3.1 Global Cancer Biopharmaceuticals Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Liquid Cancers
1.3.3 Solid Cancers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Biopharmaceuticals Market Perspective (2019-2030)
2.2 Global Cancer Biopharmaceuticals Growth Trends by Region
2.2.1 Cancer Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cancer Biopharmaceuticals Historic Market Size by Region (2019-2024)
2.2.3 Cancer Biopharmaceuticals Forecasted Market Size by Region (2025-2030)
2.3 Cancer Biopharmaceuticals Market Dynamics
2.3.1 Cancer Biopharmaceuticals Industry Trends
2.3.2 Cancer Biopharmaceuticals Market Drivers
2.3.3 Cancer Biopharmaceuticals Market Challenges
2.3.4 Cancer Biopharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Cancer Biopharmaceuticals by Players
3.1.1 Global Cancer Biopharmaceuticals Revenue by Players (2019-2024)
3.1.2 Global Cancer Biopharmaceuticals Revenue Market Share by Players (2019-2024)
3.2 Global Cancer Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Cancer Biopharmaceuticals, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Cancer Biopharmaceuticals Market Concentration Ratio
3.4.1 Global Cancer Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Biopharmaceuticals Revenue in 2023
3.5 Global Key Players of Cancer Biopharmaceuticals Head office and Area Served
3.6 Global Key Players of Cancer Biopharmaceuticals, Product and Application
3.7 Global Key Players of Cancer Biopharmaceuticals, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Biopharmaceuticals Breakdown Data by Type
4.1 Global Cancer Biopharmaceuticals Historic Market Size by Type (2019-2024)
4.2 Global Cancer Biopharmaceuticals Forecasted Market Size by Type (2025-2030)
5 Cancer Biopharmaceuticals Breakdown Data by Application
5.1 Global Cancer Biopharmaceuticals Historic Market Size by Application (2019-2024)
5.2 Global Cancer Biopharmaceuticals Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cancer Biopharmaceuticals Market Size (2019-2030)
6.2 North America Cancer Biopharmaceuticals Market Size by Type
6.2.1 North America Cancer Biopharmaceuticals Market Size by Type (2019-2024)
6.2.2 North America Cancer Biopharmaceuticals Market Size by Type (2025-2030)
6.2.3 North America Cancer Biopharmaceuticals Market Share by Type (2019-2030)
6.3 North America Cancer Biopharmaceuticals Market Size by Application
6.3.1 North America Cancer Biopharmaceuticals Market Size by Application (2019-2024)
6.3.2 North America Cancer Biopharmaceuticals Market Size by Application (2025-2030)
6.3.3 North America Cancer Biopharmaceuticals Market Share by Application (2019-2030)
6.4 North America Cancer Biopharmaceuticals Market Size by Country
6.4.1 North America Cancer Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Cancer Biopharmaceuticals Market Size by Country (2019-2024)
6.4.3 North America Cancer Biopharmaceuticals Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Cancer Biopharmaceuticals Market Size (2019-2030)
7.2 Europe Cancer Biopharmaceuticals Market Size by Type
7.2.1 Europe Cancer Biopharmaceuticals Market Size by Type (2019-2024)
7.2.2 Europe Cancer Biopharmaceuticals Market Size by Type (2025-2030)
7.2.3 Europe Cancer Biopharmaceuticals Market Share by Type (2019-2030)
7.3 Europe Cancer Biopharmaceuticals Market Size by Application
7.3.1 Europe Cancer Biopharmaceuticals Market Size by Application (2019-2024)
7.3.2 Europe Cancer Biopharmaceuticals Market Size by Application (2025-2030)
7.3.3 Europe Cancer Biopharmaceuticals Market Share by Application (2019-2030)
7.4 Europe Cancer Biopharmaceuticals Market Size by Country
7.4.1 Europe Cancer Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Cancer Biopharmaceuticals Market Size by Country (2019-2024)
7.4.3 Europe Cancer Biopharmaceuticals Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Cancer Biopharmaceuticals Market Size (2019-2030)
8.2 China Cancer Biopharmaceuticals Market Size by Type
8.2.1 China Cancer Biopharmaceuticals Market Size by Type (2019-2024)
8.2.2 China Cancer Biopharmaceuticals Market Size by Type (2025-2030)
8.2.3 China Cancer Biopharmaceuticals Market Share by Type (2019-2030)
8.3 China Cancer Biopharmaceuticals Market Size by Application
8.3.1 China Cancer Biopharmaceuticals Market Size by Application (2019-2024)
8.3.2 China Cancer Biopharmaceuticals Market Size by Application (2025-2030)
8.3.3 China Cancer Biopharmaceuticals Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Cancer Biopharmaceuticals Market Size (2019-2030)
9.2 Asia Cancer Biopharmaceuticals Market Size by Type
9.2.1 Asia Cancer Biopharmaceuticals Market Size by Type (2019-2024)
9.2.2 Asia Cancer Biopharmaceuticals Market Size by Type (2025-2030)
9.2.3 Asia Cancer Biopharmaceuticals Market Share by Type (2019-2030)
9.3 Asia Cancer Biopharmaceuticals Market Size by Application
9.3.1 Asia Cancer Biopharmaceuticals Market Size by Application (2019-2024)
9.3.2 Asia Cancer Biopharmaceuticals Market Size by Application (2025-2030)
9.3.3 Asia Cancer Biopharmaceuticals Market Share by Application (2019-2030)
9.4 Asia Cancer Biopharmaceuticals Market Size by Region
9.4.1 Asia Cancer Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Cancer Biopharmaceuticals Market Size by Region (2019-2024)
9.4.3 Asia Cancer Biopharmaceuticals Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Type
10.2.1 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Application
10.3.1 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Country
10.4.1 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Cancer Biopharmaceuticals Introduction
11.1.4 Sanofi Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.1.5 Sanofi Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Cancer Biopharmaceuticals Introduction
11.2.4 Johnson & Johnson Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.2.5 Johnson & Johnson Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Cancer Biopharmaceuticals Introduction
11.3.4 Pfizer Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.3.5 Pfizer Recent Developments
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Cancer Biopharmaceuticals Introduction
11.4.4 Novartis Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.4.5 Novartis Recent Developments
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Cancer Biopharmaceuticals Introduction
11.5.4 Merck Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.5.5 Merck Recent Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Cancer Biopharmaceuticals Introduction
11.6.4 GlaxoSmithKline Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.6.5 GlaxoSmithKline Recent Developments
11.7 Eli Lilly
11.7.1 Eli Lilly Company Details
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Cancer Biopharmaceuticals Introduction
11.7.4 Eli Lilly Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.7.5 Eli Lilly Recent Developments
11.8 Agios Pharmaceuticals
11.8.1 Agios Pharmaceuticals Company Details
11.8.2 Agios Pharmaceuticals Business Overview
11.8.3 Agios Pharmaceuticals Cancer Biopharmaceuticals Introduction
11.8.4 Agios Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.8.5 Agios Pharmaceuticals Recent Developments
11.9 Bristol-Myers Squibb
11.9.1 Bristol-Myers Squibb Company Details
11.9.2 Bristol-Myers Squibb Business Overview
11.9.3 Bristol-Myers Squibb Cancer Biopharmaceuticals Introduction
11.9.4 Bristol-Myers Squibb Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.9.5 Bristol-Myers Squibb Recent Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Company Details
11.10.2 AstraZeneca Business Overview
11.10.3 AstraZeneca Cancer Biopharmaceuticals Introduction
11.10.4 AstraZeneca Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.10.5 AstraZeneca Recent Developments
11.11 Mylan
11.11.1 Mylan Company Details
11.11.2 Mylan Business Overview
11.11.3 Mylan Cancer Biopharmaceuticals Introduction
11.11.4 Mylan Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.11.5 Mylan Recent Developments
11.12 LEO Pharma
11.12.1 LEO Pharma Company Details
11.12.2 LEO Pharma Business Overview
11.12.3 LEO Pharma Cancer Biopharmaceuticals Introduction
11.12.4 LEO Pharma Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.12.5 LEO Pharma Recent Developments
11.13 Boehringer Ingelheim
11.13.1 Boehringer Ingelheim Company Details
11.13.2 Boehringer Ingelheim Business Overview
11.13.3 Boehringer Ingelheim Cancer Biopharmaceuticals Introduction
11.13.4 Boehringer Ingelheim Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.13.5 Boehringer Ingelheim Recent Developments
11.14 Alexion Pharmaceuticals
11.14.1 Alexion Pharmaceuticals Company Details
11.14.2 Alexion Pharmaceuticals Business Overview
11.14.3 Alexion Pharmaceuticals Cancer Biopharmaceuticals Introduction
11.14.4 Alexion Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.14.5 Alexion Pharmaceuticals Recent Developments
11.15 Elusys Therapeutics
11.15.1 Elusys Therapeutics Company Details
11.15.2 Elusys Therapeutics Business Overview
11.15.3 Elusys Therapeutics Cancer Biopharmaceuticals Introduction
11.15.4 Elusys Therapeutics Revenue in Cancer Biopharmaceuticals Business (2019-2024)
11.15.5 Elusys Therapeutics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Cancer Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of Biologics
Table 3. Key Players of Biosimilars
Table 4. Global Cancer Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Global Cancer Biopharmaceuticals Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Cancer Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Cancer Biopharmaceuticals Market Share by Region (2019-2024)
Table 8. Global Cancer Biopharmaceuticals Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Cancer Biopharmaceuticals Market Share by Region (2025-2030)
Table 10. Cancer Biopharmaceuticals Market Trends
Table 11. Cancer Biopharmaceuticals Market Drivers
Table 12. Cancer Biopharmaceuticals Market Challenges
Table 13. Cancer Biopharmaceuticals Market Restraints
Table 14. Global Cancer Biopharmaceuticals Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Cancer Biopharmaceuticals Revenue Share by Players (2019-2024)
Table 16. Global Top Cancer Biopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biopharmaceuticals as of 2023)
Table 17. Global Cancer Biopharmaceuticals Industry Ranking 2022 VS 2023 VS 2024
Table 18. Global 5 Largest Players Market Share by Cancer Biopharmaceuticals Revenue (CR5 and HHI) & (2019-2024)
Table 19. Global Key Players of Cancer Biopharmaceuticals, Headquarters and Area Served
Table 20. Global Key Players of Cancer Biopharmaceuticals, Product and Application
Table 21. Global Key Players of Cancer Biopharmaceuticals, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Cancer Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2019-2024)
Table 25. Global Cancer Biopharmaceuticals Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2025-2030)
Table 27. Global Cancer Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Cancer Biopharmaceuticals Revenue Share by Application (2019-2024)
Table 29. Global Cancer Biopharmaceuticals Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Cancer Biopharmaceuticals Revenue Share by Application (2025-2030)
Table 31. North America Cancer Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 32. North America Cancer Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 33. North America Cancer Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 34. North America Cancer Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 35. North America Cancer Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Cancer Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Cancer Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Cancer Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 39. Europe Cancer Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 40. Europe Cancer Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 41. Europe Cancer Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 42. Europe Cancer Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Europe Cancer Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)
Table 44. Europe Cancer Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)
Table 45. China Cancer Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 46. China Cancer Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 47. China Cancer Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 48. China Cancer Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 49. Asia Cancer Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 50. Asia Cancer Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 51. Asia Cancer Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 52. Asia Cancer Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 53. Asia Cancer Biopharmaceuticals Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 54. Asia Cancer Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)
Table 55. Asia Cancer Biopharmaceuticals Market Size by Region (2025-2030) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 61. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)
Table 63. Sanofi Company Details
Table 64. Sanofi Business Overview
Table 65. Sanofi Cancer Biopharmaceuticals Product
Table 66. Sanofi Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 67. Sanofi Recent Developments
Table 68. Johnson & Johnson Company Details
Table 69. Johnson & Johnson Business Overview
Table 70. Johnson & Johnson Cancer Biopharmaceuticals Product
Table 71. Johnson & Johnson Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 72. Johnson & Johnson Recent Developments
Table 73. Pfizer Company Details
Table 74. Pfizer Business Overview
Table 75. Pfizer Cancer Biopharmaceuticals Product
Table 76. Pfizer Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 77. Pfizer Recent Developments
Table 78. Novartis Company Details
Table 79. Novartis Business Overview
Table 80. Novartis Cancer Biopharmaceuticals Product
Table 81. Novartis Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 82. Novartis Recent Developments
Table 83. Merck Company Details
Table 84. Merck Business Overview
Table 85. Merck Cancer Biopharmaceuticals Product
Table 86. Merck Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 87. Merck Recent Developments
Table 88. GlaxoSmithKline Company Details
Table 89. GlaxoSmithKline Business Overview
Table 90. GlaxoSmithKline Cancer Biopharmaceuticals Product
Table 91. GlaxoSmithKline Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 92. GlaxoSmithKline Recent Developments
Table 93. Eli Lilly Company Details
Table 94. Eli Lilly Business Overview
Table 95. Eli Lilly Cancer Biopharmaceuticals Product
Table 96. Eli Lilly Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 97. Eli Lilly Recent Developments
Table 98. Agios Pharmaceuticals Company Details
Table 99. Agios Pharmaceuticals Business Overview
Table 100. Agios Pharmaceuticals Cancer Biopharmaceuticals Product
Table 101. Agios Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 102. Agios Pharmaceuticals Recent Developments
Table 103. Bristol-Myers Squibb Company Details
Table 104. Bristol-Myers Squibb Business Overview
Table 105. Bristol-Myers Squibb Cancer Biopharmaceuticals Product
Table 106. Bristol-Myers Squibb Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 107. Bristol-Myers Squibb Recent Developments
Table 108. AstraZeneca Company Details
Table 109. AstraZeneca Business Overview
Table 110. AstraZeneca Cancer Biopharmaceuticals Product
Table 111. AstraZeneca Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 112. AstraZeneca Recent Developments
Table 113. Mylan Company Details
Table 114. Mylan Business Overview
Table 115. Mylan Cancer Biopharmaceuticals Product
Table 116. Mylan Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 117. Mylan Recent Developments
Table 118. LEO Pharma Company Details
Table 119. LEO Pharma Business Overview
Table 120. LEO Pharma Cancer Biopharmaceuticals Product
Table 121. LEO Pharma Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 122. LEO Pharma Recent Developments
Table 123. Boehringer Ingelheim Company Details
Table 124. Boehringer Ingelheim Business Overview
Table 125. Boehringer Ingelheim Cancer Biopharmaceuticals Product
Table 126. Boehringer Ingelheim Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 127. Boehringer Ingelheim Recent Developments
Table 128. Alexion Pharmaceuticals Company Details
Table 129. Alexion Pharmaceuticals Business Overview
Table 130. Alexion Pharmaceuticals Cancer Biopharmaceuticals Product
Table 131. Alexion Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 132. Alexion Pharmaceuticals Recent Developments
Table 133. Elusys Therapeutics Company Details
Table 134. Elusys Therapeutics Business Overview
Table 135. Elusys Therapeutics Cancer Biopharmaceuticals Product
Table 136. Elusys Therapeutics Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)
Table 137. Elusys Therapeutics Recent Developments
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Biopharmaceuticals Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Cancer Biopharmaceuticals Market Share by Type: 2023 VS 2030
Figure 3. Biologics Features
Figure 4. Biosimilars Features
Figure 5. Global Cancer Biopharmaceuticals Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 6. Global Cancer Biopharmaceuticals Market Share by Application: 2023 VS 2030
Figure 7. Liquid Cancers Case Studies
Figure 8. Solid Cancers Case Studies
Figure 9. Cancer Biopharmaceuticals Report Years Considered
Figure 10. Global Cancer Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Cancer Biopharmaceuticals Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Cancer Biopharmaceuticals Market Share by Region: 2023 VS 2030
Figure 13. Global Cancer Biopharmaceuticals Market Share by Players in 2023
Figure 14. Global Top Cancer Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biopharmaceuticals as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Cancer Biopharmaceuticals Revenue in 2023
Figure 16. North America Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Cancer Biopharmaceuticals Market Share by Type (2019-2030)
Figure 18. North America Cancer Biopharmaceuticals Market Share by Application (2019-2030)
Figure 19. North America Cancer Biopharmaceuticals Market Share by Country (2019-2030)
Figure 20. United States Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Cancer Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 23. Europe Cancer Biopharmaceuticals Market Share by Type (2019-2030)
Figure 24. Europe Cancer Biopharmaceuticals Market Share by Application (2019-2030)
Figure 25. Europe Cancer Biopharmaceuticals Market Share by Country (2019-2030)
Figure 26. Germany Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. China Cancer Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 33. China Cancer Biopharmaceuticals Market Share by Type (2019-2030)
Figure 34. China Cancer Biopharmaceuticals Market Share by Application (2019-2030)
Figure 35. Asia Cancer Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 36. Asia Cancer Biopharmaceuticals Market Share by Type (2019-2030)
Figure 37. Asia Cancer Biopharmaceuticals Market Share by Application (2019-2030)
Figure 38. Asia Cancer Biopharmaceuticals Market Share by Region (2019-2030)
Figure 39. Japan Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. South Korea Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. China Taiwan Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Southeast Asia Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. India Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Australia Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Share by Type (2019-2030)
Figure 47. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Share by Application (2019-2030)
Figure 48. Middle East, Africa, and Latin America Cancer Biopharmaceuticals Market Share by Country (2019-2030)
Figure 49. Brazil Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Mexico Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Turkey Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Israel Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. GCC Countries Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. Sanofi Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 56. Johnson & Johnson Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 57. Pfizer Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 58. Novartis Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 59. Merck Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 60. GlaxoSmithKline Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 61. Eli Lilly Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 62. Agios Pharmaceuticals Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 64. AstraZeneca Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 65. Mylan Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 66. LEO Pharma Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 67. Boehringer Ingelheim Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 68. Alexion Pharmaceuticals Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 69. Elusys Therapeutics Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies